JSH-23

JSH-23 is an NF-κB inhibitor which inhibits NF-κB transcriptional activity with an IC50 of 7.1 μM in lipopolysaccharide (LPS) -stimulated macrophages RAW 264.7. JSH-23 inhibits nuclear translocation of NF-κB p65 without affecting IκBα degradation[1].

Product Specifications

CAS Number

[749886-87-1]

UNSPSC

12352005

Hazard Statement

H302, H318, H400

Target

NF-κB

Type

Reference compound

Related Pathways

NF-κB

Applications

Cancer-programmed cell death

Field of Research

Cancer; Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/JSH-23.html

Purity

99.92

Solubility

DMSO : ≥ 56 mg/mL

Smiles

NC1=CC(C)=CC=C1NCCCC2=CC=CC=C2

Molecular Formula

C16H20N2

Molecular Weight

240.34

Precautions

H302, H318, H400

References & Citations

[1]Shin HM, et al. Inhibitory action of novel aromatic diamine compound on lipopolysaccharide-induced nuclear translocation of NF-kappaB without affecting IkappaB degradation. FEBS Lett. 2004 Jul 30;571 (1-3) :50-4.|[2]Kumar A, et al. JSH-23 targets nuclear factor-kappa B and reverses various deficits in experimental diabetic neuropathy: effect on neuroinflammation and antioxidant defence. Diabetes Obes Metab. 2011 Aug;13 (8) :750-8.